ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Ustekinumab Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-31P7667
Home | Market Reports | Health| Pharmacy
Global Ustekinumab Market Insights and Forecast to 2028
BUY CHAPTERS

Global Ustekinumab Market Research Report 2025

Code: QYRE-Auto-31P7667
Report
August 2025
Pages:95
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Meiji
Johnson & Johnson
Alvotech
Fuji Pharma
Mitsubishi Tanabe
STADA
EPIRUS BioPharma
Formycon AG
NeuClone
Bio-Thera Solutions
Huadong Medicine
Amgen Inc
Sandoz Inc
Biocon Biologics

Ustekinumab Market Size

The global market for Ustekinumab was valued at US$ 21831 million in the year 2024 and is projected to reach a revised size of US$ 32612 million by 2031, growing at a CAGR of 5.9% during the forecast period.

Ustekinumab Market

Ustekinumab Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Ustekinumab competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Ustekinumab is a fully human IgG1κ monoclonal antibody that specifically binds to the p40 protein subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), blocking their interaction with cell surface receptors and suppressing related inflammatory responses. It is indicated for the treatment of immune-mediated disorders such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. In 2024, the production volume of ustekinumab was 6.12 million syringes, with an average price of USD 3,566 per syringe.
Market Overview
From 2024 to 2025 the ustekinumab landscape has pivoted to multi-biosimilar competition: the EU moved first in January 2024 (Uzpruvo by STADA/Alvotech), Japan approvals were in place since 2023 (Fuji Pharma with Alvotech), China granted its first domestic approval in October 2024 (Huadong Medicine/QX001S), and the U.S. became a crowded arena in 1H25 with several launches (Selarsdi by Teva/Alvotech, Otulfi by Fresenius Kabi/Formycon, Imuldosa by Dong-A ST/Meiji/Accord, and Starjemza by Hikma/Bio-Thera). J&J’s ex-U.S. Stelara sales started to feel intensified pressure as biosimilars expanded geographically.
Regional Structure
Based on approval/launch timing, access dynamics and the originator’s disclosed regional trends, the estimated 1H25 revenue split for ustekinumab (originator + biosimilars) is: United States 62%, Europe 18%, Japan 7%, China 5%, Rest of World 8% (summing to 100%). The EU’s early 2024 launches reduced the originator’s share, the U.S. turned competitive in 2025 with interchangeable products and dual IV/SC formulations, while Japan and China—despite approvals—remain smaller in absolute value versus the U.S. This estimate is anchored to J&J’s regional sales structure and the actual approval/launch cadence.
Key Manufacturers & Competition
Active players include the originator Johnson & Johnson; biosimilar entrants Teva/Alvotech (Selarsdi; interchangeable), STADA/Alvotech (Uzpruvo in the EU), Fresenius Kabi/Formycon (Otulfi; interchangeable; IV and SC), Dong-A ST/Meiji/Accord (Imuldosa; US/EU approvals with UK/IE launches), Hikma/Bio-Thera (Starjemza; US), plus Fuji Pharma (Japan commercialization with Alvotech) and Huadong Medicine (first domestic approval in China). Competition is driven by interchangeability, full-route coverage (SC + IV), industrial scale/release cycle, and access/contracting speed. NeuClone remains earlier-stage; EPIRUS BioPharma has no recent authoritative disclosures tied to this asset.
Technology Trends & Innovation
The focus is on tight analytical/clinical matching plus differentiation via “interchangeability,” full-formulation portfolios (SC and IV), high-concentration prefilled devices/auto-injectors, and robust global CMC/release networks. Otulfi’s interchangeable designation with both IV and SC underscores the advantage of complete modality coverage; Alvotech’s centralized Reykjavik manufacturing combined with regional commercialization partners exemplifies a “central-make, local-sell” operating model.
Policy & Growth Drivers
Clear regulatory pathways and frequent approvals across the U.S./EU/Japan, together with Europe’s procurement-driven uptake and the U.S. patent expiry in 2025, are elevating price competition and substitution rates. China’s first domestic approval in 2024 and subsequent indication filings improve affordability and access. In Japan, coordinated promotion arrangements (e.g., with Mitsubishi Tanabe) remain relevant during the transition.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Ustekinumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ustekinumab.
The Ustekinumab market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Ustekinumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ustekinumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Ustekinumab Market Report

Report Metric Details
Report Name Ustekinumab Market
Accounted market size in year US$ 21831 million
Forecasted market size in 2031 US$ 32612 million
CAGR 5.9%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Intravenous
  • Subcutaneous
Segment by Application
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Meiji, Johnson & Johnson, Alvotech, Fuji Pharma, Mitsubishi Tanabe, Stada, EPIRUS BioPharma, Formycon, NeuClone, Bio-Thera Solutions, Huadong Medicine, Amgen, Sandoz, Biocon Biologics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Ustekinumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Ustekinumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Ustekinumab Market growing?

Ans: The Ustekinumab Market witnessing a CAGR of 5.9% during the forecast period 2025-2031.

What is the Ustekinumab Market size in 2031?

Ans: The Ustekinumab Market size in 2031 will be US$ 32612 million.

Who are the main players in the Ustekinumab Market report?

Ans: The main players in the Ustekinumab Market are Meiji, Johnson & Johnson, Alvotech, Fuji Pharma, Mitsubishi Tanabe, Stada, EPIRUS BioPharma, Formycon, NeuClone, Bio-Thera Solutions, Huadong Medicine, Amgen, Sandoz, Biocon Biologics

What are the Application segmentation covered in the Ustekinumab Market report?

Ans: The Applications covered in the Ustekinumab Market report are Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Others

What are the Type segmentation covered in the Ustekinumab Market report?

Ans: The Types covered in the Ustekinumab Market report are Intravenous, Subcutaneous

1 Ustekinumab Market Overview
1.1 Product Definition
1.2 Ustekinumab by Type
1.2.1 Global Ustekinumab Market Value Comparison by Type (2024 VS 2031)
1.2.2 Intravenous
1.2.3 Subcutaneous
1.3 Ustekinumab by Application
1.3.1 Global Ustekinumab Market Value by Application (2024 VS 2031)
1.3.2 Plaque Psoriasis
1.3.3 Psoriatic Arthritis
1.3.4 Crohn’s Disease
1.3.5 Ulcerative Colitis
1.3.6 Others
1.4 Global Ustekinumab Market Size Estimates and Forecasts
1.4.1 Global Ustekinumab Revenue 2020-2031
1.4.2 Global Ustekinumab Sales 2020-2031
1.4.3 Global Ustekinumab Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Ustekinumab Market Competition by Manufacturers
2.1 Global Ustekinumab Sales Market Share by Manufacturers (2020-2025)
2.2 Global Ustekinumab Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Ustekinumab Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Ustekinumab, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Ustekinumab, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Ustekinumab, Product Type & Application
2.7 Global Key Manufacturers of Ustekinumab, Date of Enter into This Industry
2.8 Global Ustekinumab Market Competitive Situation and Trends
2.8.1 Global Ustekinumab Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Ustekinumab Players Market Share by Revenue
2.8.3 Global Ustekinumab Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Ustekinumab Market Scenario by Region
3.1 Global Ustekinumab Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Ustekinumab Sales by Region: 2020-2031
3.2.1 Global Ustekinumab Sales by Region: 2020-2025
3.2.2 Global Ustekinumab Sales by Region: 2026-2031
3.3 Global Ustekinumab Revenue by Region: 2020-2031
3.3.1 Global Ustekinumab Revenue by Region: 2020-2025
3.3.2 Global Ustekinumab Revenue by Region: 2026-2031
3.4 North America Ustekinumab Market Facts & Figures by Country
3.4.1 North America Ustekinumab Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Ustekinumab Sales by Country (2020-2031)
3.4.3 North America Ustekinumab Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Ustekinumab Market Facts & Figures by Country
3.5.1 Europe Ustekinumab Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Ustekinumab Sales by Country (2020-2031)
3.5.3 Europe Ustekinumab Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ustekinumab Market Facts & Figures by Region
3.6.1 Asia Pacific Ustekinumab Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Ustekinumab Sales by Region (2020-2031)
3.6.3 Asia Pacific Ustekinumab Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Ustekinumab Market Facts & Figures by Country
3.7.1 Latin America Ustekinumab Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Ustekinumab Sales by Country (2020-2031)
3.7.3 Latin America Ustekinumab Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ustekinumab Market Facts & Figures by Country
3.8.1 Middle East and Africa Ustekinumab Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Ustekinumab Sales by Country (2020-2031)
3.8.3 Middle East and Africa Ustekinumab Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Ustekinumab Sales by Type (2020-2031)
4.1.1 Global Ustekinumab Sales by Type (2020-2025)
4.1.2 Global Ustekinumab Sales by Type (2026-2031)
4.1.3 Global Ustekinumab Sales Market Share by Type (2020-2031)
4.2 Global Ustekinumab Revenue by Type (2020-2031)
4.2.1 Global Ustekinumab Revenue by Type (2020-2025)
4.2.2 Global Ustekinumab Revenue by Type (2026-2031)
4.2.3 Global Ustekinumab Revenue Market Share by Type (2020-2031)
4.3 Global Ustekinumab Price by Type (2020-2031)
5 Segment by Application
5.1 Global Ustekinumab Sales by Application (2020-2031)
5.1.1 Global Ustekinumab Sales by Application (2020-2025)
5.1.2 Global Ustekinumab Sales by Application (2026-2031)
5.1.3 Global Ustekinumab Sales Market Share by Application (2020-2031)
5.2 Global Ustekinumab Revenue by Application (2020-2031)
5.2.1 Global Ustekinumab Revenue by Application (2020-2025)
5.2.2 Global Ustekinumab Revenue by Application (2026-2031)
5.2.3 Global Ustekinumab Revenue Market Share by Application (2020-2031)
5.3 Global Ustekinumab Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Meiji
6.1.1 Meiji Company Information
6.1.2 Meiji Description and Business Overview
6.1.3 Meiji Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Meiji Ustekinumab Product Portfolio
6.1.5 Meiji Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Company Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Johnson & Johnson Ustekinumab Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Alvotech
6.3.1 Alvotech Company Information
6.3.2 Alvotech Description and Business Overview
6.3.3 Alvotech Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Alvotech Ustekinumab Product Portfolio
6.3.5 Alvotech Recent Developments/Updates
6.4 Fuji Pharma
6.4.1 Fuji Pharma Company Information
6.4.2 Fuji Pharma Description and Business Overview
6.4.3 Fuji Pharma Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Fuji Pharma Ustekinumab Product Portfolio
6.4.5 Fuji Pharma Recent Developments/Updates
6.5 Mitsubishi Tanabe
6.5.1 Mitsubishi Tanabe Company Information
6.5.2 Mitsubishi Tanabe Description and Business Overview
6.5.3 Mitsubishi Tanabe Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Mitsubishi Tanabe Ustekinumab Product Portfolio
6.5.5 Mitsubishi Tanabe Recent Developments/Updates
6.6 Stada
6.6.1 Stada Company Information
6.6.2 Stada Description and Business Overview
6.6.3 Stada Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Stada Ustekinumab Product Portfolio
6.6.5 Stada Recent Developments/Updates
6.7 EPIRUS BioPharma
6.7.1 EPIRUS BioPharma Company Information
6.7.2 EPIRUS BioPharma Description and Business Overview
6.7.3 EPIRUS BioPharma Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.7.4 EPIRUS BioPharma Ustekinumab Product Portfolio
6.7.5 EPIRUS BioPharma Recent Developments/Updates
6.8 Formycon
6.8.1 Formycon Company Information
6.8.2 Formycon Description and Business Overview
6.8.3 Formycon Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Formycon Ustekinumab Product Portfolio
6.8.5 Formycon Recent Developments/Updates
6.9 NeuClone
6.9.1 NeuClone Company Information
6.9.2 NeuClone Description and Business Overview
6.9.3 NeuClone Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.9.4 NeuClone Ustekinumab Product Portfolio
6.9.5 NeuClone Recent Developments/Updates
6.10 Bio-Thera Solutions
6.10.1 Bio-Thera Solutions Company Information
6.10.2 Bio-Thera Solutions Description and Business Overview
6.10.3 Bio-Thera Solutions Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Bio-Thera Solutions Ustekinumab Product Portfolio
6.10.5 Bio-Thera Solutions Recent Developments/Updates
6.11 Huadong Medicine
6.11.1 Huadong Medicine Company Information
6.11.2 Huadong Medicine Description and Business Overview
6.11.3 Huadong Medicine Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Huadong Medicine Ustekinumab Product Portfolio
6.11.5 Huadong Medicine Recent Developments/Updates
6.12 Amgen
6.12.1 Amgen Company Information
6.12.2 Amgen Description and Business Overview
6.12.3 Amgen Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Amgen Ustekinumab Product Portfolio
6.12.5 Amgen Recent Developments/Updates
6.13 Sandoz
6.13.1 Sandoz Company Information
6.13.2 Sandoz Description and Business Overview
6.13.3 Sandoz Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Sandoz Ustekinumab Product Portfolio
6.13.5 Sandoz Recent Developments/Updates
6.14 Biocon Biologics
6.14.1 Biocon Biologics Company Information
6.14.2 Biocon Biologics Description and Business Overview
6.14.3 Biocon Biologics Ustekinumab Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Biocon Biologics Ustekinumab Product Portfolio
6.14.5 Biocon Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Ustekinumab Industry Chain Analysis
7.2 Ustekinumab Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ustekinumab Production Mode & Process Analysis
7.4 Ustekinumab Sales and Marketing
7.4.1 Ustekinumab Sales Channels
7.4.2 Ustekinumab Distributors
7.5 Ustekinumab Customer Analysis
8 Ustekinumab Market Dynamics
8.1 Ustekinumab Industry Trends
8.2 Ustekinumab Market Drivers
8.3 Ustekinumab Market Challenges
8.4 Ustekinumab Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Meiji
Johnson & Johnson
Alvotech
Fuji Pharma
Mitsubishi Tanabe
STADA
EPIRUS BioPharma
Formycon AG
NeuClone
Bio-Thera Solutions
Huadong Medicine
Amgen Inc
Sandoz Inc
Biocon Biologics
List of Tables
 Table 1. Global Ustekinumab Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Ustekinumab Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Ustekinumab Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Ustekinumab Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Ustekinumab Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Ustekinumab Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Ustekinumab Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Ustekinumab Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Ustekinumab, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Ustekinumab, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Ustekinumab, Product Type & Application
 Table 12. Global Key Manufacturers of Ustekinumab, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Ustekinumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ustekinumab as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Ustekinumab Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Ustekinumab Sales by Region (2020-2025) & (K Units)
 Table 18. Global Ustekinumab Sales Market Share by Region (2020-2025)
 Table 19. Global Ustekinumab Sales by Region (2026-2031) & (K Units)
 Table 20. Global Ustekinumab Sales Market Share by Region (2026-2031)
 Table 21. Global Ustekinumab Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Ustekinumab Revenue Market Share by Region (2020-2025)
 Table 23. Global Ustekinumab Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Ustekinumab Revenue Market Share by Region (2026-2031)
 Table 25. North America Ustekinumab Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Ustekinumab Sales by Country (2020-2025) & (K Units)
 Table 27. North America Ustekinumab Sales by Country (2026-2031) & (K Units)
 Table 28. North America Ustekinumab Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Ustekinumab Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Ustekinumab Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Ustekinumab Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Ustekinumab Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Ustekinumab Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Ustekinumab Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Ustekinumab Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Ustekinumab Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Ustekinumab Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Ustekinumab Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Ustekinumab Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Ustekinumab Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Ustekinumab Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Ustekinumab Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Ustekinumab Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Ustekinumab Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Ustekinumab Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Ustekinumab Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Ustekinumab Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Ustekinumab Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Ustekinumab Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Ustekinumab Sales (K Units) by Type (2020-2025)
 Table 51. Global Ustekinumab Sales (K Units) by Type (2026-2031)
 Table 52. Global Ustekinumab Sales Market Share by Type (2020-2025)
 Table 53. Global Ustekinumab Sales Market Share by Type (2026-2031)
 Table 54. Global Ustekinumab Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Ustekinumab Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Ustekinumab Revenue Market Share by Type (2020-2025)
 Table 57. Global Ustekinumab Revenue Market Share by Type (2026-2031)
 Table 58. Global Ustekinumab Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Ustekinumab Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Ustekinumab Sales (K Units) by Application (2020-2025)
 Table 61. Global Ustekinumab Sales (K Units) by Application (2026-2031)
 Table 62. Global Ustekinumab Sales Market Share by Application (2020-2025)
 Table 63. Global Ustekinumab Sales Market Share by Application (2026-2031)
 Table 64. Global Ustekinumab Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Ustekinumab Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Ustekinumab Revenue Market Share by Application (2020-2025)
 Table 67. Global Ustekinumab Revenue Market Share by Application (2026-2031)
 Table 68. Global Ustekinumab Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Ustekinumab Price (US$/Unit) by Application (2026-2031)
 Table 70. Meiji Company Information
 Table 71. Meiji Description and Business Overview
 Table 72. Meiji Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Meiji Ustekinumab Product
 Table 74. Meiji Recent Developments/Updates
 Table 75. Johnson & Johnson Company Information
 Table 76. Johnson & Johnson Description and Business Overview
 Table 77. Johnson & Johnson Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Johnson & Johnson Ustekinumab Product
 Table 79. Johnson & Johnson Recent Developments/Updates
 Table 80. Alvotech Company Information
 Table 81. Alvotech Description and Business Overview
 Table 82. Alvotech Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Alvotech Ustekinumab Product
 Table 84. Alvotech Recent Developments/Updates
 Table 85. Fuji Pharma Company Information
 Table 86. Fuji Pharma Description and Business Overview
 Table 87. Fuji Pharma Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Fuji Pharma Ustekinumab Product
 Table 89. Fuji Pharma Recent Developments/Updates
 Table 90. Mitsubishi Tanabe Company Information
 Table 91. Mitsubishi Tanabe Description and Business Overview
 Table 92. Mitsubishi Tanabe Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Mitsubishi Tanabe Ustekinumab Product
 Table 94. Mitsubishi Tanabe Recent Developments/Updates
 Table 95. Stada Company Information
 Table 96. Stada Description and Business Overview
 Table 97. Stada Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Stada Ustekinumab Product
 Table 99. Stada Recent Developments/Updates
 Table 100. EPIRUS BioPharma Company Information
 Table 101. EPIRUS BioPharma Description and Business Overview
 Table 102. EPIRUS BioPharma Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. EPIRUS BioPharma Ustekinumab Product
 Table 104. EPIRUS BioPharma Recent Developments/Updates
 Table 105. Formycon Company Information
 Table 106. Formycon Description and Business Overview
 Table 107. Formycon Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Formycon Ustekinumab Product
 Table 109. Formycon Recent Developments/Updates
 Table 110. NeuClone Company Information
 Table 111. NeuClone Description and Business Overview
 Table 112. NeuClone Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. NeuClone Ustekinumab Product
 Table 114. NeuClone Recent Developments/Updates
 Table 115. Bio-Thera Solutions Company Information
 Table 116. Bio-Thera Solutions Description and Business Overview
 Table 117. Bio-Thera Solutions Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Bio-Thera Solutions Ustekinumab Product
 Table 119. Bio-Thera Solutions Recent Developments/Updates
 Table 120. Huadong Medicine Company Information
 Table 121. Huadong Medicine Description and Business Overview
 Table 122. Huadong Medicine Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Huadong Medicine Ustekinumab Product
 Table 124. Huadong Medicine Recent Developments/Updates
 Table 125. Amgen Company Information
 Table 126. Amgen Description and Business Overview
 Table 127. Amgen Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Amgen Ustekinumab Product
 Table 129. Amgen Recent Developments/Updates
 Table 130. Sandoz Company Information
 Table 131. Sandoz Description and Business Overview
 Table 132. Sandoz Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Sandoz Ustekinumab Product
 Table 134. Sandoz Recent Developments/Updates
 Table 135. Biocon Biologics Company Information
 Table 136. Biocon Biologics Description and Business Overview
 Table 137. Biocon Biologics Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Biocon Biologics Ustekinumab Product
 Table 139. Biocon Biologics Recent Developments/Updates
 Table 140. Key Raw Materials Lists
 Table 141. Raw Materials Key Suppliers Lists
 Table 142. Ustekinumab Distributors List
 Table 143. Ustekinumab Customers List
 Table 144. Ustekinumab Market Trends
 Table 145. Ustekinumab Market Drivers
 Table 146. Ustekinumab Market Challenges
 Table 147. Ustekinumab Market Restraints
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Ustekinumab
 Figure 2. Global Ustekinumab Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Ustekinumab Market Share by Type: 2024 & 2031
 Figure 4. Intravenous Product Picture
 Figure 5. Subcutaneous Product Picture
 Figure 6. Global Ustekinumab Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Ustekinumab Market Share by Application: 2024 & 2031
 Figure 8. Plaque Psoriasis
 Figure 9. Psoriatic Arthritis
 Figure 10. Crohn’s Disease
 Figure 11. Ulcerative Colitis
 Figure 12. Others
 Figure 13. Global Ustekinumab Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Ustekinumab Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Ustekinumab Sales (2020-2031) & (K Units)
 Figure 16. Global Ustekinumab Average Price (US$/Unit) & (2020-2031)
 Figure 17. Ustekinumab Report Years Considered
 Figure 18. Ustekinumab Sales Share by Manufacturers in 2024
 Figure 19. Global Ustekinumab Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Ustekinumab Players: Market Share by Revenue in Ustekinumab in 2024
 Figure 21. Ustekinumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Ustekinumab Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Ustekinumab Sales Market Share by Country (2020-2031)
 Figure 24. North America Ustekinumab Revenue Market Share by Country (2020-2031)
 Figure 25. U.S. Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Ustekinumab Sales Market Share by Country (2020-2031)
 Figure 28. Europe Ustekinumab Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Ustekinumab Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Ustekinumab Revenue Market Share by Region (2020-2031)
 Figure 36. China Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Taiwan Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Indonesia Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Thailand Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Malaysia Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Philippines Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America Ustekinumab Sales Market Share by Country (2020-2031)
 Figure 47. Latin America Ustekinumab Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa Ustekinumab Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa Ustekinumab Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. UAE Ustekinumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of Ustekinumab by Type (2020-2031)
 Figure 57. Global Revenue Market Share of Ustekinumab by Type (2020-2031)
 Figure 58. Global Ustekinumab Price (US$/Unit) by Type (2020-2031)
 Figure 59. Global Sales Market Share of Ustekinumab by Application (2020-2031)
 Figure 60. Global Revenue Market Share of Ustekinumab by Application (2020-2031)
 Figure 61. Global Ustekinumab Price (US$/Unit) by Application (2020-2031)
 Figure 62. Ustekinumab Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Ustekinumab Biosimilars Market Research Report 2024
Stelara Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Arthritis Monoclonal Antibodies Market Research Report 2024
Global Secukinumab Market Research Report 2024
Global Infliximab Injection Market Research Report 2024
Global Tocilizumab Drugs Market Research Report 2024
Global Ipilimumab Market Research Report 2024
Global Granulocytes Monoclonal Antibody Market Research Report 2024
Adalimumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti TNF α Monoclonal Antibody Market Insights Forecast to 2030
Global Ubiquitin Monoclonal Antibody Market Research Report 2024
Global Dupilumab Injection Market Research Report 2024
Global Tocilizumab Market Research Report 2024
Global Lipopolysaccharides Monoclonal Antibody Market Research Report 2024
Global Fibronectin Monoclonal Antibody Market Research Report 2024
Global IL 17 Monoclonal Antibody Injections Market Research Report 2024
Global Radotinib Market Research Report 2024
Global Therapeutic Monoclonal Antibodies Market Research Report 2024
Global Myeloperoxidase Monoclonal Antibody Market Research Report 2024
Global CAMKI Antibody Market Research Report 2024

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions